RecruitingNot Applicable

Improving Patient Assessment After Acute Kidney Injury (AKI)

United Kingdom100 participantsStarted 2026-02-16

Plain-language summary

The goal of this clinical trial is to improve patient care after acute kidney injury (AKI). It has three related parts. The main questions it aims to answer are: 1. Is creatinine or cystatin a more reliable assessment of kidney function after AKI? 2. What are the experiences of patients after AKI? 3. What interventions should be recommended to improve assessment and support of patients after AKI? Participants will be asked to do one or more of: * blood tests to measure kidney function in different ways * have measurement of their body composition * complete questionnaires about their symptoms * have an interview with a researcher about their experiences * discussion to develop an action plan based on findings

Who can participate

Age range

18 Years – 85 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Observational study workstream * Age 18-85 years * AKI stage 2 or 3 during hospital admission OR AKI stage 1 of at least 7 days duration during hospital admission * 60-90 days after peak creatinine Qualitative interview workstream * Age 18-85 years * AKI during hospital admission * 60-90 days after peak creatinine Participatory workshop workstream * Age 18-85 years * Relevant experience (as assessed by the investigator) which could include personal experience of an episode of hospitalised AKI as a patient of carer, experience of managing AKI or related problems in a professional capacity or knowledge of a particular community. Exclusion Criteria: Observational study workstream * Inability to give informed consent * No baseline creatinine available in previous 12 months * Pregnancy or breastfeeding * Current treatment with dialysis * Renal transplant * Pacemaker in situ * Previous amputation * Allergy to Omnipaque contrast agent (WP1 only) * Manifest thyrotoxicosis (WP1 only) * Ascites or significant (grade 3 to 4) peripheral oedema, defined as ≥6 mm pit, lasting for \>1 minute after 5-second compression over tibia or medial malleolus (WP1 only) Qualitative interview workstream * Inability to give informed consent * No baseline creatinine available in previous 12 months * Current treatment with dialysis * Renal transplant * Receiving palliative care Participatory workshop workstream * Inability to give informed consent * Inability to communicate in Eng…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

The proportion of eligible patients who agree to participate

Timeframe: 3 months

The proportion of participants who have all three measurements (eGFR-cystatin, eGFR-creatinine and measured GFR)

Timeframe: 3 months

Standard deviation of the difference between measured GFR and eGFR-creatinine and eGFR-cystatin

Timeframe: 3 months

The proportion of patients with eGFR <60ml/min/1.73m2 from eGFR-cystatin compared with eGFR creatinine

Timeframe: 3 months

Gut microbiome composition

Timeframe: 3 months

Codes and themes related to patient experience after AKI, identified from systematic qualitative analysis of interview transcripts

Timeframe: 3 - 12 months

Production of a document of recommended next steps through MDT development during participatory workshops

Timeframe: At completion of third workshop 3 years after enrolment

Trial details

NCT IDNCT07569588

SponsorUniversity of Nottingham

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-01

Contact for this trial

Kerry Horne Dr, BMBCh

+44 01332 788262 kerry.horne@nottingham.ac.uk

View on ClinicalTrials.gov More Acute Kidney Injury trials

Plain-language summary

Who can participate

Age range

18 Years – 85 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

The proportion of eligible patients who agree to participate

Timeframe: 3 months

The proportion of participants who have all three measurements (eGFR-cystatin, eGFR-creatinine and measured GFR)

Timeframe: 3 months

Standard deviation of the difference between measured GFR and eGFR-creatinine and eGFR-cystatin

Timeframe: 3 months

The proportion of patients with eGFR <60ml/min/1.73m2 from eGFR-cystatin compared with eGFR creatinine

Timeframe: 3 months

Gut microbiome composition

Timeframe: 3 months

Codes and themes related to patient experience after AKI, identified from systematic qualitative analysis of interview transcripts

Timeframe: 3 - 12 months

Production of a document of recommended next steps through MDT development during participatory workshops

Timeframe: At completion of third workshop 3 years after enrolment